Filing Flows › Acadia Pharmaceuticals (ACAD) › Q1 2025
Acadia Pharmaceuticals (ACAD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Acadia Pharmaceuticals (ACAD) reported revenue of $244M for the first quarter 2025 (Q1 2025), +19% from a year earlier and -6% from the quarter before. Operating margin was 7.9%, net earnings $19.0M (7.8% of revenue).
Acadia Pharmaceuticals, Q1 2025: revenue $244M (+19% year over year), operating margin 7.9%, net earnings $19.0M, operating cash flow $20.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $244M | -6% | +19% |
| Operating profit | $19.3M | -87% | +27% |
| Net earnings | $19.0M | -87% | +15% |
| Operating cash flow | $20.3M | -50% | -30% |
What changed
Revenue was $244.3M in Q1 2025, up 19% year over year and down 6% from the previous quarter.
Operating profit was $19.3M, a 7.9% margin (up 0.5 points year over year). Of the extra revenue versus a year earlier, 11% reached operating profit, above the 7% margin then. Total costs grew 18% against revenue growth of 19%. The fastest-growing cost line was Research & development (+31%). Net earnings were $19.0M, up 15% year over year. The effective tax rate was 31.6%. Non-operating items added $8.5M, 31% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $20.3M (down 30% year over year), 107% of net earnings. Non-cash charges added back $3.0M of depreciation and amortization and $11.4M of share-based compensation. Working capital and other items used $13.0M.
Questions
What was Acadia Pharmaceuticals' revenue in the first quarter 2025?
Acadia Pharmaceuticals (ACAD) reported revenue of $244M for the first quarter 2025 (Q1 2025), +19% from a year earlier and -6% from the quarter before.
Was Acadia Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $19.3M (7.9% of revenue) and net earnings $19.0M.